Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Interventions: DRUG: Trastuzumab Emtansine for Injection|DRUG: Pyrotinib Maleate Tablets
Sponsor: Tianjin Medical University Cancer Institute and Hospital